The stock may re-rate on sustained organic growth, margin improvement, and strong 2026 guidance. Watch for execution on PNS product launch and cash flow conversion. Short interest could compress if momentum continues.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $9.10entry
- T+1 · 9mo ago −7.58%α −6.27% · $8.41
- T+5 · 8mo ago −5.49%α −3.26% · $8.60
- T+20 · 8mo ago −1.43%α +2.36% · $8.97
- T+60 · 6mo ago −12.86%α −24.16% · $7.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability improvement, and raised 2026 guidance projecting 6-7% revenue growth and 7-13% adjusted EPS growth. The company exited a divestiture-impacted year with improved margins and cash flow, signaling operational strength.
Key Financial Metrics
Key Facts
- Q4 revenue: $157.9M, up 2.8% reported, 10.0% organic; driven by double-digit growth in Pain Treatments and Surgical Solutions
- Q4 GAAP EPS: $0.21 vs. $0.00 in prior year; Non-GAAP EPS: $0.24 vs. $0.26 in prior year
- Full-year 2025 revenue: $568.1M, down 0.9% reported (due to divestiture), up 7.5% organically
- Full-year 2025 GAAP EPS: $0.33 vs. loss of $0.56; Adjusted EPS: $0.68, up 21.4% YoY
- 2026 guidance: Revenue $600M–$610M (~6-7% growth), Adjusted EPS $0.73–$0.77 (~7-13% growth), CFO: $82M–$87M
- Q4 cash from operations: $38.0M, up 97% YoY; full-year CFO up 92%
- Reduced debt by $29M in Q4, strengthened balance sheet
Financial Impact
Revenue growth accelerating organically, earnings normalized to profitability, and 2026 guidance implies continued margin expansion. $32M+ increase in annual revenue guidance and ~$0.05 EPS uplift projected.
Risk Factors
- Adjusted EPS declined slightly YoY despite revenue and operating income growth, due to tax headwinds
- Restorative Therapies segment still under pressure post-divestiture, though EXOGEN showing organic recovery
- Forward guidance excludes GAAP net income, limiting visibility on full profitability trajectory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249987 |
Track record
18 reports on BVS
2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers